You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb News) – Active Motif announced Thursday that it has acquired privately held genomics tools maker SwitchGear Genomics for an undisclosed price.
NEW YORK (GenomeWeb News) – SwitchGear Genomics today said it has partnered with New England Biolabs to develop a new dual reporter assay system.
Cosmo Bio will distribute the LightSwitch Luciferase Assay System with marketing and technical support from SwitchGear.
BioCat will distribute the firm's LightSwitch Luciferase Assay System in select European countries.
Under the distribution agreement, SwitchGear will offer the reagent as a standalone product as well as part of its own LightSwitch Transfection Optimization kit.
The collaboration brings together SwitchGear's expertise in gene regulatory networks and Sigma-Aldrich's lentiviral technology and is expected to result in a genome-wide collection of target vectors.
The method combines Promega's HaloCHIP DNA-protein complex capture technology and SwitchGear's high-throughput promoter assays.
The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.
UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.
President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.
In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.